Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 8/20 | 0.36 |
| ▸ | DRD3 | P35462 | 7/20 | 0.36 |
| ▸ | HTR1D | P28221 | 3/20 | 0.36 |
| ▸ | DRD4 | P21917 | 4/20 | 0.34 |
| ▸ | DRD1 | P21728 | 2/20 | 0.34 |
| ▸ | DRD5 | P21918 | 2/20 | 0.34 |
| ▸ | HTR5A | P47898 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2637284 | 0.94 | DRD2 (0.33) | DRD2DRD3HTR1DDRD4DRD1 | |
| SCHEMBL22165875 | 0.84 | DRD2 (0.33) | DRD2DRD3HTR1DDRD4DRD1 | |
| SCHEMBL1302897 | 0.84 | DRD2 (0.33) | DRD2DRD3HTR1DDRD4DRD1 | |
| SCHEMBL23093104 | 0.82 | DRD2 (0.35) | DRD2DRD3DRD4DRD1DRD5 | |
| SCHEMBL23203461 | 0.82 | DRD2 (0.35) | DRD2DRD3DRD4DRD1DRD5 | |
| SCHEMBL17256540 | 0.81 | DRD2 (0.32) | DRD2DRD3HTR1DDRD4DRD1 | |
| SCHEMBL2178698 | 0.80 | DRD2 (0.37) | DRD2DRD3HTR1DDRD4DRD1 | |
| SCHEMBL28567223 | 0.80 | DRD2 (0.34) | DRD2DRD3HTR1DDRD4DRD1 | |
| SCHEMBL16661136 | 0.80 | DRD2 (0.31) | DRD2DRD3HTR1D | |
| SCHEMBL19449967 | 0.78 | DRD2 (0.34) | DRD2DRD3HTR1DDRD4DRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9096624-B2 | Amino pyrimidine anticancer compounds | OSI Pharmaceuticals, LLC (US) | 2015-08-04 | — | — | US | disclosed |
| US-20130231306-A1 | AMINO PYRIMIDINE ANTICANCER COMPOUNDS | OSI Pharmaceuticals, LLC (US) | 2013-09-05 | — | — | US | disclosed |
| US-8399433-B2 | Amino pyrimidine anticancer compounds | OSI Pharmaceuticals, LLC (US) | 2013-03-19 | — | — | US | disclosed |
| EP-2438056-A2 | AMINO PYRIMIDINE ANTICANCER COMPOUNDS | OSI Pharmaceuticals, LLC (US) | 2012-04-11 | — | — | EP | disclosed |
| US-20110136764-A1 | AMINO PYRIMIDINE ANTICANCER COMPOUNDS | OSI PHARMACEUTICALS, INC. (US) | 2011-06-09 | — | — | US | disclosed |
| WO-2010141406-A2 | AMINO PYRIMIDINE ANTICANCER COMPOUNDS | OSI PHARMACEUTICALS, INC. (US) | 2010-12-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130231306-A1 | AMINO PYRIMIDINE ANTICANCER COMPOUNDS | DPYD, PTK2, TYMS | DRD2 4412/4885DRD3 4670/4885HTR1D 1547/4885 |
| US-20110136764-A1 | AMINO PYRIMIDINE ANTICANCER COMPOUNDS | DPYD, PTK2, TYMS | DRD2 4412/4885DRD3 4670/4885HTR1D 1547/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.